Welcome
From one colorectal cancer patient to another
I am a molecular biologist, and I was diagnosed in my late thirties. This is where I put what the evidence actually says about what you can do alongside standard treatment: new research explained in plain language, and the book I wish someone had handed me on day one.
-
Bevacizumab triplet had 0.99 probability of top surgical-conversion ranking
Across seven randomised trials in initially unresectable colorectal liver metastases, bevacizumab plus triplet chemotherapy ranked highest for disease control and conversion to R0-1 surgery. That ranking drew partly…
-
Tislelizumab regimen reached 45.3% pathological complete response in rectal cancer
In this 118-patient randomised phase II trial, adding tislelizumab to short-course radiotherapy and CAPOX chemotherapy was associated with a higher pathological complete response rate than the same treatment…
-
First-line immunotherapy reduced progression hazard 39% in MSI-H metastatic colorectal cancer
A meta-analysis of two randomised phase III trials found longer progression-free and overall survival with first-line checkpoint-inhibitor therapy than chemotherapy in MSI-H/dMMR metastatic colorectal cancer. The evidence is…
-
The saliva microbiome might help detect early-onset colorectal cancer.
In a prospective cohort of 128 people, a machine-learning model using saliva bacteria distinguished people with early-onset colorectal cancer from healthy controls with an AUC of 0.780. This…
-
Updated PHTS surveillance guidance includes colorectal cancer, but evidence remains limited
This ERN GENTURIS expert guideline updates cancer surveillance advice for people with PTEN hamartoma tumour syndrome, including colorectal cancer surveillance. It is based on a literature review and…
-
Cetuximab-irinotecan produced 18.8 versus 10.4 months median survival
In a 68-patient exploratory randomised trial, rechallenge with cetuximab plus irinotecan produced longer median progression-free and overall survival than regorafenib. The result is promising but comes from one…
These summaries are education, not medical advice. A single new study rarely changes what you should do. Discuss anything here with your oncology team before acting on it.
The book behind this site
The Colorectal Cancer Blueprint
What the evidence actually supports alongside standard treatment, with every recommendation graded for evidence quality, effect size and safety.
Written by Andreas Porse, a molecular biologist who is also a colorectal cancer patient. Most people leave surgery and chemotherapy without being told that diet, exercise, supplements and a handful of common pharmacy drugs can move their recurrence risk. This book closes that gap, and is honest about where the evidence is thin.
- 31chapters
- 360+studies cited
- 60+illustrations
- 579pages, Kindle edition
Figures from the book and the complete contents are on the book page.
Keep up with the research
New colorectal cancer research, screened and explained in plain language, sent when there is something genuinely worth reading. Roughly monthly, never more than that.
One email when there is something worth reading, usually monthly. No advertising, no selling your address, unsubscribe in one click.